Literature DB >> 25849422

In vivo secretion of anti-CD3 × anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement.

Marta Compte1, Laura Sanz1, Luis Álvarez-Vallina2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25849422      PMCID： PMC4395791          DOI： 10.1038/mt.2015.36

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

Review 1.  The therapeutic potential of engineered human neovessels for cell-based gene therapy.

Authors:  Luís Alvarez-Vallina; Laura Sanz
Journal:  Expert Opin Biol Ther       Date:  2010-11-17       Impact factor: 4.388

2.  Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system.

Authors:  M Compte; V Alonso-Camino; P Santos-Valle; A M Cuesta; D Sánchez-Martín; M R López; J L Vicario; C Salas; L Sanz; L Alvarez-Vallina
Journal:  Gene Ther       Date:  2010-03-25       Impact factor: 5.250

3.  Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins.

Authors:  David Sánchez-Martín; Laura Sanz; Luis Álvarez-Vallina
Journal:  Curr Opin Biotechnol       Date:  2011-03-22       Impact factor: 9.740

Review 4.  Non-hematopoietic stem cells as factories for in vivo therapeutic protein production.

Authors:  L Sanz; M Compte; I Guijarro-Muñoz; L Álvarez-Vallina
Journal:  Gene Ther       Date:  2011-05-12       Impact factor: 5.250

5.  Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.

Authors:  Kota Iwahori; Sunitha Kakarla; Mireya P Velasquez; Feng Yu; Zongzhen Yi; Claudia Gerken; Xiao-Tong Song; Stephen Gottschalk
Journal:  Mol Ther       Date:  2014-08-21       Impact factor: 11.454

Review 6.  Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all?

Authors:  Laura Sanz; Jian Qiao; Richard G Vile; Luis Alvarez-Vallina
Journal:  Curr Gene Ther       Date:  2005-02       Impact factor: 4.391

7.  Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells.

Authors:  Belén Blanco; Phillip Holliger; Richard G Vile; Luis Alvarez-Vallina
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

Review 8.  Antibodies and gene therapy: teaching old 'magic bullets' new tricks.

Authors:  Laura Sanz; Belén Blanco; Luis Alvarez-Vallina
Journal:  Trends Immunol       Date:  2004-02       Impact factor: 16.687

9.  Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.

Authors:  M Compte; B Blanco; F Serrano; A M Cuesta; L Sanz; A Bernad; P Holliger; L Alvarez-Vallina
Journal:  Cancer Gene Ther       Date:  2007-01-12       Impact factor: 5.987

10.  Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applications.

Authors:  Marta Compte; Ana Alvarez-Cienfuegos; Natalia Nuñez-Prado; Noelia Sainz-Pastor; Ana Blanco-Toribio; Nuria Pescador; Laura Sanz; Luis Alvarez-Vallina
Journal:  Oncoimmunology       Date:  2014-05-23       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.